Tandem Diabetes Acquires Swiss Based Insulin Patch Pump Developer

Tandem Diabetes Care Inc (NASDAQ:TNDM) has agreed to acquire AMF Medical SA, the privately held Swiss developer of the investigational Sigi…
  • Tandem Diabetes Care Inc (NASDAQ:TNDM) has agreed to acquire AMF Medical SA, the privately held Swiss developer of the investigational Sigi Patch Pump.
  • It is designed to be an ergonomic, rechargeable patch pump that reduces the burden of managing diabetes through its use of pre-filled insulin cartridges and its compatibility with automated insulin delivery technology.
  • The acquisition expands Tandem’s type 1 and type 2 addressable market opportunities.
  • Tandem Diabetes Care will acquire AMF Medical under the following financial terms of the agreement:
  • A previous strategic investment of CHF 8.0 million was paid in Q3 of 2022.
  • A cash payment of CHF 62.4 million is due at closing.
  • Additional contingent earnout payments of up to CHF 129.6 million, in aggregate, are payable upon achieving certain milestones.
  • The transaction is expected to close in January 2023.
  • Price Action: TNDM shares are down 3.40% at $42.16 on the last check Tuesday.
Total
0
Shares
Related Posts
Read More

Ocuphire Pharma Announces First Patient Enrolled In LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) For The Treatment Of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner ViatrisFARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage

OCUP